Pancreatic Cancer Research

ResearcherTufts UniversityActive in the last 2 years

Suzanne M. Russo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4144-4711; OpenAlex author ID A5017355670. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 4 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 11

  1. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Revie… Last author DOI 10.1097/coc.0000000000001076↗
  2. Neoadjuvant therapy for pancreatic cancer: an ongoing debate. Co-author DOI 10.1177/1756283x16646524↗
  3. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Co-author DOI 10.1586/14737140.2016.1168698↗
  4. 2016 Gastrointestinal Cancers Symposium: update on pancreatic cancer. Co-author DOI 10.20524/aog.2016.0024↗
  5. The role of neoadjuvant therapy in pancreatic cancer: a review. Co-author DOI 10.2217/fon.15.335↗
  6. Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. Co-author PMID 26637914↗
  7. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. First author DOI 10.1586/era.12.18↗
  8. Adjuvant strategies for resectable pancreatic cancer: have we made progress? Co-author DOI 10.6092/1590-8577/689↗
  9. Resectable pancreatic cancer: is surgery the best first step? Co-author DOI 10.6092/1590-8577/697↗
  10. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally… Co-author DOI 10.1007/s00280-010-1383-0↗
  11. Identification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Franc… Co-author PMID 21386628↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Muhammad Wasif Saif · 5 shared papers, 2011–2016 · strength 0.33
  2. William C. Small · 2 shared papers, 2016–2024 · strength 0.23
  3. Christopher Leigh Hallemeier · 1 shared paper, 2024 · strength 0.18
  4. Leila T. Tchelebi · 1 shared paper, 2024 · strength 0.18
  5. Rachit Kumar · 1 shared paper, 2024 · strength 0.18
  6. Krishan R. Jethwa · 1 shared paper, 2024 · strength 0.18
  7. Jordan D. Berlin · 1 shared paper, 2024 · strength 0.18
  8. Salma K. Jabbour · 1 shared paper, 2024 · strength 0.18
  9. Percy P. Lee · 1 shared paper, 2024 · strength 0.18
  10. Jennifer Anne Dorth · 2 shared papers, 2016 · strength 0.14
  11. Jennifer Rachel Eads · 1 shared paper, 2016 · strength 0.08
  12. John Brian Ammori · 1 shared paper, 2016 · strength 0.08
  13. Bryan William Chang · 1 shared paper, 2015 · strength 0.06
  14. Kathryn E. Huber · 1 shared paper, 2015 · strength 0.06
  15. Matthew J. Abrams · 1 shared paper, 2015 · strength 0.06
  16. Rodney J. Ellis · 1 shared paper, 2016 · strength 0.05
  17. Lauren M. Rosati · 1 shared paper, 2016 · strength 0.05
  18. Simon Shek-Man Lo · 1 shared paper, 2016 · strength 0.05
  19. Sten D. Myrehaug · 1 shared paper, 2016 · strength 0.05
  20. Joseph M. Herman · 1 shared paper, 2016 · strength 0.05
  21. Bin Sing Teh · 1 shared paper, 2016 · strength 0.05
  22. John A. Chabot · 1 shared paper, 2012 · strength 0.05
  23. Arthur William Blackstock · 1 shared paper, 2012 · strength 0.04
  24. Arta Monir Monjazeb · 1 shared paper, 2012 · strength 0.04
  25. Randall J. Kimple · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.